Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 02'nd Apr 2024
Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript
12:49pm, Tuesday, 26'th Mar 2024
Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
09:41am, Tuesday, 26'th Mar 2024
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.86 per share a year ago.
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
07:30am, Tuesday, 26'th Mar 2024
Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y. , March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional onc
Delcath Systems Closes $7 Million Private Placement
08:15am, Wednesday, 20'th Mar 2024
NEW YORK, March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
09:00am, Tuesday, 19'th Mar 2024
NEW YORK , March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced t
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
05:20pm, Monday, 18'th Mar 2024
NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cance
Delcath Systems Announces $7 Million Private Placement
08:20am, Friday, 15'th Mar 2024
NEW YORK , March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 08'th Mar 2024
NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer
Delcath Systems to Participate in Upcoming Investor Conferences
09:00am, Friday, 08'th Mar 2024
NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today annou
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
05:00pm, Thursday, 22'nd Feb 2024
NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today annou
Penny Stocks To Buy Now? 4 To Watch Before 2024
10:11am, Tuesday, 19'th Dec 2023
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
Penny Stocks To Buy Today? 3 To Watch Before Thanksgiving
03:01pm, Tuesday, 21'st Nov 2023
Is the stock market open on Thanksgiving? No, but that doesn't mean the shortened holiday week won't be packed with stock market moving catalysts.
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
06:40pm, Friday, 17'th Nov 2023
Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperfo
Delcath Systems Inc. (DCTH) Q3 2023 Earnings Call Transcript
10:07pm, Monday, 13'th Nov 2023
Delcath Systems Inc. (NASDAQ:DCTH ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO San
